All 3 treatments have been shown to significantly improve progression-free survival (PFS) in HR+, HER2− advanced breast cancer when combined with ET in the first or second line [4–12], with ribociclib and abemaciclib also shown to significantly improve overall survival (OS) in these settings [13–17]. This evidence concerns the gene ERBB2 and breast carcinoma.